Literature DB >> 6970110

Effect of cardiopulmonary bypass on fentanyl distribution and elimination.

A J Koska, A Romagnoli, W G Kramer.   

Abstract

Fentanyl kinetics was studied in two groups of six patients, one group undergoing surgery with and one without cardiopulmonary bypass; the latter served as the controls. Plasma fentanyl concentrations declined biexponentially in the control patients with an average half-life (t1/2 beta) of 3.3 +/- 1.1 hr, total plasma clearance of 11.2 +/- 3.4 ml/min/kg, and volume of distribution (Vd beta) of 3.2 +/- 1.5 l/kg. The plasma concentration/time curves were severely disrupted during cardiopulmonary bypass but appeared to regain a log-linear decay once bypass was complete. This elimination phase had a t1/2 of 5.2 +/- 2.7 hr, longer than that in the control patients. Since fentanyl is eliminated primarily by hepatic metabolism, decreased liver plasma flow observed during and after bypass, as evidenced by a 30% decrease in indocyanine green clearance, may contribute to the extended t1/2. The prolonged t1/2 had clinical importance because of potentially prolonged effects and their relation to other drugs and the clinical management of the patient.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6970110     DOI: 10.1038/clpt.1981.16

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

Review 1.  The pharmacokinetic behaviour of opioids administered during cardiac surgery.

Authors:  R Hall
Journal:  Can J Anaesth       Date:  1991-09       Impact factor: 5.063

Review 2.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 3.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

4.  Sufentanil disposition during cardiopulmonary bypass.

Authors:  P Flezzani; M J Alvis; J R Jacobs; M M Schilling; S Bai; J G Reves
Journal:  Can J Anaesth       Date:  1987-11       Impact factor: 5.063

Review 5.  Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.

Authors:  J Scholz; M Steinfath; M Schulz
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 6.  Effect of cardiopulmonary bypass on the pharmacokinetics of drugs.

Authors:  F O Holley; K V Ponganis; D R Stanski
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

7.  CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients.

Authors:  Rajiv Balyan; Marc Mecoli; Raja Venkatasubramanian; Vidya Chidambaran; Nichole Kamos; Smokey Clay; David L Moore; Jagroop Mavi; Chris D Glover; Peter Szmuk; Alexander Vinks; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2017-02-17       Impact factor: 2.533

8.  The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children.

Authors:  Enno D Wildschut; Annewil van Saet; Pavla Pokorna; Maurice J Ahsman; John N Van den Anker; Dick Tibboel
Journal:  Pediatr Clin North Am       Date:  2012-08-29       Impact factor: 3.278

9.  The influence of hypothermia on the disposition of fentanyl--human and animal studies.

Authors:  G Koren; C Barker; G Goresky; D Bohn; G Kent; J Klein; S M MacLeod; W D Biggar
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Pharmacokinetics of alfentanil and clinical responses during cardiac surgery.

Authors:  G R Robbins; J E Wynands; D G Whalley; F Donati; J G Ramsay; C B Srikant; Y C Patel
Journal:  Can J Anaesth       Date:  1990-01       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.